We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+5.61%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$489M
AUM Growth
-$71.9M
Cap. Flow
-$18.9M
Cap. Flow %
-3.87%
Top 10 Hldgs %
88.2%
Holding
39
New
2
Increased
1
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$18.1M
2
ALMS
Alumis Inc
ALMS
+$7.25M
3
AURA icon
Aura Biosciences
AURA
+$5.85M

Top Sells

Rank Stock Value
1
PVLA
Palvella Therapeutics
PVLA
+$7.97M
2
SLRN
ACELYRIN
SLRN
+$6.23M
3
UPB
Upstream Bio Inc
UPB
+$5.76M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$5.37M
5
LENZ
LENZ Therapeutics
LENZ
+$4.99M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARTV
26
Artiva Biotherapeutics
ARTV
$566M
$440K 0.09%
291,666
– –
BOLT icon
27
Bolt Biotherapeutics
BOLT
$7.44M
$303K 0.06%
52,456
-2
-0% -$13
NUVB.WS
28
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$36K 0.01%
133,333
– –
SRZNW icon
29
Surrozen Inc Warrant
SRZNW
$22.4K
$1.81K ﹤0.01%
99,999
– –
ABVX
30
Abivax
ABVX
$11.3B
– –
-425,000
Closed -$2.66M
ALLK
31
DELISTED
Allakos
ALLK
– –
-172,089
Closed -$39.2K
CRIS icon
32
Curis
CRIS
$8.59M
– –
-9,297
Closed -$390K
INZY
33
DELISTED
Inozyme Pharma
INZY
– –
-1,562,500
Closed -$1.42M
KRON
34
DELISTED
Kronos Bio
KRON
– –
-78,131
Closed -$64.5K
CYPH
35
Cypherpunk Technologies Inc
CYPH
$71.7M
– –
-2,442,352
Closed -$745K
LYRA
36
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-27,803
Closed -$176K
PRME icon
37
Prime Medicine
PRME
$533M
– –
-405,228
Closed -$806K
SLRN
38
DELISTED
ACELYRIN
SLRN
– –
-2,523,022
Closed -$6.23M
OKUR
39
OnKure Therapeutics
OKUR
$168M
– –
-824,155
Closed -$3.54M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Samsara BioCapital's Q2 2025 Portfolio in Review

As of Q2 2025, Samsara BioCapital held 39 positions worth $489M, down 13% from $561M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Samsara BioCapital withdrew a net $18.9M in Q2 2025, closing 10 positions and reducing 9 holdings. Its most notable exit was ACELYRIN, an estimated $6.23M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Jade Biosciences worth $5.31M.

  • Samsara BioCapital's largest Q2 2025 buy was Jade Biosciences: 531,163 shares worth $5.31M.
  • Samsara BioCapital added most to Alumis Inc in Q2 2025, an estimated $7.25M increase.
  • Samsara BioCapital's biggest Q2 2025 reduction was Palvella Therapeutics, cutting an estimated $7.97M.
  • Samsara BioCapital fully exited ACELYRIN in Q2 2025, selling an estimated $6.23M.
  • Samsara BioCapital's ten largest holdings make up 88% of its $489M portfolio in Q2 2025.
  • Samsara BioCapital opened 2 new positions and closed 10 in Q2 2025.
  • Samsara BioCapital's portfolio value fell 13% quarter-over-quarter to $489M.

Based on Samsara BioCapital's 13F filing for Q2 2025, filed 14 Aug 2025.